2025 AHA/ACC Clinical Performance and Quality Measures for Patients With Chronic Coronary Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures [0.03%]
2025年美国心脏协会/美国心脏病学会慢性冠心病临床绩效和质量措施：美国心脏病学基金会/美国心脏协会联合委员会的报告
Marlene S Williams,Glenn N Levine,Dinesh Kalra et al.
Marlene S Williams et al.
Chronic coronary disease (CCD) is the leading cause of death in the United States. There is an ongoing imperative to disseminate evidence-based and patient-centered care recommendations that further align the management of patients with CCD...
Proactive Electrophysiological Mapping and Ablation to Prevent Ventricular Tachycardia in Repaired Tetralogy of Fallot [0.03%]
主动进行心电生理检查和消融以预防法洛四联症术后患者室性心动过速复发
Christian Meyer,Kalyanam Shivkumar
Christian Meyer
Proactive Mapping and Preventive Ablation Reduce Defibrillator Implantation Rates in Tetralogy of Fallot [0.03%]
主动标测和预防性消融可减少法洛四联症除颤器植入率
Yoshitaka Kimura,Justin Wallet,Charlotte Brouwer et al.
Yoshitaka Kimura et al.
Background: In patients with repaired tetralogy of Fallot (rTOF) and spontaneous ventricular tachycardia (VT), transection of slow-conducting anatomical isthmus (SCAI) by ablation results in excellent long-term VT-free su...
Sudden Cardiac Arrest in Athletes: The Need for Legislation and Data-Informed Implementation [0.03%]
运动员心脏骤停：立法和数据驱动的实施方案的需求
Marius Chukwurah,Jeomi Okwara,Anezi Uzendu
Marius Chukwurah
Pulse Field Ablation for Persistent Atrial Fibrillation: Does Posterior Wall Isolation Improve Outcomes? [0.03%]
持续性心房颤动脉冲场消融后壁隔离改善结局吗？
Amier Ahmad,Rahul N Doshi
Amier Ahmad
Pulsed Field Ablation for Persistent Atrial Fibrillation: 1-Year Results of ADVANTAGE AF [0.03%]
用于持续性房颤的脉冲场消融：ADVANTAGE AF研究1年结果
Vivek Y Reddy,Edward P Gerstenfeld,Boris Schmidt et al.
Vivek Y Reddy et al.
Background: Pulsed field ablation (PFA) has gained prominence for pulmonary vein isolation (PVI) to treat atrial fibrillation, but there are limited outcome data on PFA to treat persistent atrial fibrillation (PerAF). ...
Finerenone for Prevention of First-Detected AF Across the Cardio-Kidney-Metabolic Spectrum: Insights From the FINE-HEART Pooled Analysis [0.03%]
心血管-肾脏-代谢谱系首次检测到的房颤的预防：来自FINE-HEART荟萃分析的洞见
Jonathan P Piccini,Adam D DeVore,Marat Fudim
Jonathan P Piccini
Finerenone Reduces New-Onset Atrial Fibrillation Across the Spectrum of Cardio-Kidney-Metabolic Syndrome: The FINE-HEART Pooled Analysis [0.03%]
芬戈利尤单抗可降低心血管-肾脏-代谢综合征谱系的新发房颤：来自FINE-HEART汇总分析的证据
Maria A Pabon,Gerasimos Filippatos,Brian L Claggett et al.
Maria A Pabon et al.
Background: Mineralocorticoid receptor antagonists (MRA) modulate cardiac and systemic pathways such as fibrosis and inflammation, which may contribute to the onset of atrial fibrillation (AF) or atrial flutter (AFL). ...
Randomized Controlled Trial
Journal of the American College of Cardiology. 2025 May 6;85(17):1649-1660. DOI:10.1016/j.jacc.2025.03.429 2025
Advancing Electrophysiology: Innovations, Challenges, and the Future of Arrhythmia Management [0.03%]
电生理学的创新、挑战及心律失常治疗的未来
Harlan M Krumholz
Harlan M Krumholz
Oral PCSK9 Inhibitors: Can Novel Therapies Overcome Barriers to Effective LDL-Cholesterol Management? [0.03%]
口服PCSK9抑制剂：新的疗法能否克服有效降低低密度脂蛋白胆固醇的障碍？
Christie M Ballantyne,Alberico L Catapano,Khurram Nasir
Christie M Ballantyne